地特胰岛素联合瑞格列奈对初发2型糖尿病疗效的观察

摘要

目的：评价地特胰岛素联合瑞格列奈对初发2型糖尿病患者血糖和体重的影响.方法：初发2型糖尿病患者60例,随机分为两组,分别于睡前皮下注射地特胰岛素(n=30)或甘精胰岛素(n=30).两组均联合口服瑞格列奈(1 mg,3次/d)治疗12周,比较两组治疗前后空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、体重、低血糖的变化.结果：与治疗前比较,两组FPG、2 h PG、HbA1c均明显下降,差异均有统计学意义(P<0.05).两组低血糖发生率差异无统计学意义(P>0.05),而地特胰岛素组体重增加明显低于甘精胰岛素组(P<0.05).结论：对初发2型糖尿病,与甘精胰岛素相比,地特胰岛素联合瑞格列奈可有效控制血糖,在减少体重增加方面更有优势.%　　Objective:To evaluate the influence of insulin detemir combined repaglinide on blood sugar and weight in onset type 2 diabetes patients. Method:60 cases onset of type 2 diabetes patients were randomly divided into two groups,subcutaneous injection detemir group(n=30)and insulin glargine group(n=30)respectively in bedtime. Both groups combined oral repaglinide(1 mg,tid)through 12 weeks treatment and to compare the change of fasting plasma glucose(FPG),2 h postprandial plasma glucose(2 h PG),glycated hemoglobin(HbA1c),weight,incidence of hypoglycemia before and after treatment.Result:Compared with before treatment,FPG,2 h PG,HbA1c in both groups were significantly decreased,and the differences were statistically significant(P<0.05).The incidence of hypoglycemia between two groups had no significant difference(P>0.05),and the weight gain in detemir group was significantly lower than the insulin glargine group(P<0.01). Conclusion:Regardless of Detemir or insulin glargine combined repaglinide can control blood glucose effectively for the onset of type 2 diabetes patients,detemir is more advantages in reducing weight gain.